Immunotherapy
Entity.
- Evidence
- 650 documents · 151 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 21 Oct 2026
- Measured
- 5% of mentions say something specific about it; the rest only name it
- As of
- 22 Oct 2026
Where this comes from
- Crit Rev Oncol Hematol · 2026-10-20 · The evolution of immunotherapy resistance in mismatch repair-deficient colorectal cancer: A spatiotemporal perspective. (opens the source in a new tab)
- J Immunother Cancer · 2026-10-20 · Observation versus maintenance immunotherapy after PD-1-induced clinical complete response in dMMR/MSI-H colorectal cancer managed non-operatively: a multicenter co… (opens the source in a new tab)
- FDA D.I.S.C.O. · 2026-10-19 · FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery (opens the source in a new tab)
- European Medical Journal · 2026-10-16 · Olive Pollen Immunotherapy Linked to Improved Allergy Symptoms (opens the source in a new tab)
- Cell Host Microbe · 2026-10-16 · Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer. (opens the source in a new tab)
- RSC Adv · 2026-10-16 · A lectin-directed antibody-recruiting molecule against Tn antigen for cancer immunotherapy. (opens the source in a new tab)
- J Gastrointest Cancer · 2026-10-15 · Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H/dMMR Metastatic Colorectal Cancer: A Review. (opens the source in a new tab)
- European Medical Journal · 2026-10-15 · Peanut Immunotherapy Reduces Allergy Markers in Infants: BSACI 2026 (opens the source in a new tab)
- The ASCO Post · 2026-10-15 · Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma (opens the source in a new tab)
- European Medical Journal · 2026-10-14 · Immunotherapy Before Liver Transplant Linked to Improved Survival (opens the source in a new tab)
- Nat Immunol · 2026-10-14 · Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. (opens the source in a new tab)